Given increasing healthcare spending, rising research and development (R&D) in personalized medicine, several advancements in genetic engineering, regulatory support, and the rapid adoption of AI, the biotechnology industry is well-poised to witness robust growth in the foreseeable future.
Given the industry’s bright prospects, it could be wise to invest in fundamentally strong biotech stocks Royalty Pharma plc (RPRX), Anika Therapeutics, Inc. (ANIK), and Innoviva, Inc. (INVA) this month.
